SNC-Lavalin Wins Construction Contract for New Hemosol
Facility
MONTREAL, CANADA--NOVEMBER 13, 2000 - 15:25 EST
SNC-Lavalin has been awarded an EPC
(Engineering, Procurement, Construction) contract from Hemosol, a
Canadian biopharmaceutical company, for the design and
construction of a new facility in Mississauga, Ontario. The
facility will include a manufacturing area of about 45,000 square
feet which will meet stringent national and international
regulations and guidelines in the drug and pharmaceutical
industries. The facility is expected to be operational by early
2002 with validation and licensing to follow later in the year.
The contract awarded to SNC-Lavalin's Pellemon division is valued
at approximately $50 million.
Earlier this year, Pellemon was awarded the contract for the
overall validation of the projected facility, an essential element
of compliance for the Canadian Therapeutic Products Program,
American Food and Drug Administration and European authorities.
Hemosol will use its new installations to produce Hemolink(TM), a
highly purified human-derived hemoglobin replacement product
manufactured through a series of proprietary processes. In
addition to a longer shelf life than donor blood - a full year
compared to only 42 days - Hemolink(TM) provides greater safety
from viral and bacterial contamination, universal compatibility
with all blood types, efficient oxygen delivery to tissues and
reduced risks of allergic or immune reactions.
SNC-Lavalin Group is one of the leading engineering and
construction firms in the world, and a key player in the ownership
and management of infrastructure. The group and its companies
have offices across Canada and in 30 other countries, and are
currently working in some 100 countries. The company is listed on
the Toronto Stock Exchange (symbol: SNC). |
